GlassScriptPhysician profile
Deborah A Brauer
NPI 1700031481
$3,587.79
in general payments reported to CMS, 2019-2025
26 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $442 · 2021: $525 · 2022: $554 · 2023: $424 · 2024: $366 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Education: $20.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.75 |
| Education | $20.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,391.08 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $373.65 | 2019-2025 | Xifaxan |
| Pfizer INC. | $261.64 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $260.70 | 2019-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $244.44 | 2020-2025 | Rebyota |
| Janssen Biotech, INC. | $191.39 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Ucb, INC. | $166.29 | 2019-2020 | |
| Genzyme Corporation | $73.11 | 2022-2023 | |
| Romark Laboratories, Lc | $72.80 | 2020 | |
| Celgene Corporation | $54.25 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $53.59 | 2019-2020 | |
| Gilead Sciences, INC. | $52.76 | 2019-2022 | |
| Daiichi Sankyo INC. | $45.21 | 2019 | |
| Medtronic, INC. | $41.29 | 2022 | |
| Braintree Laboratories, INC. | $36.17 | 2020-2024 | Sutab, Suflave |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $35.70 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $35.44 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $33.36 | 2021-2022 | |
| Stryker Corporation | $33.12 | 2025 | Neptune |
| Ironwood Pharmaceuticals, INC | $21.43 | 2024 | |
| Celltrion USA INC. | $20.87 | 2024 | Zymfentra |
| Novo Nordisk INC | $20.84 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $19.53 | 2022 | |
| Ardelyx, INC. | $17.35 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $17.00 | 2023 | |
| Alfasigma USA, INC. | $14.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Brauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.